ABSTRACT
Buprenorphine treatment has an established history of reducing opioid overdoses; however, extended-release naltrexone does not have the same track record. This study evaluates the risk of patients with opioid use disorder experiencing an acute-care incident treated with extended-release naltrexone compared to those treated with buprenorphine. A generalized estimating equation was used to estimate the association of days in treatment with extended-release naltrexone or buprenorphine with the need for emergency room or inpatient acute care in a sample of 29,727 people with private insurance in the United States. The study found that for every day in treatment with either medication there was a 10% reduction in the odds of experiencing an acute-care incident during the course of a month. The apparent parity of extended-release naltrexone and buprenorphine in reducing overdose and other acute-care incidents emphasizes the need for prescribers to make all medications for opioid use disorder available to treatment seekers.
Disclosure statement
No potential conflict of interest was reported by the author(s).